AAPL350.69+8.32 (+2.43%) ▲|ABBV293.30+1.99 (+0.68%) ▲|ABT110.51+0.58 (+0.53%) ▲|ACN254.37-6.13 (-2.35%) ▼|ADBE237.32-1.98 (-0.83%) ▼|AMAT370.55+37.84 (+11.37%) ▲|AMD508.58+59.54 (+13.26%) ▲|AMGN465.23+4.81 (+1.04%) ▲|AMT189.00+0.21 (+0.11%) ▲|AMZN266.93+7.63 (+2.94%) ▲|AVGO319.48+25.79 (+8.78%) ▲|AXP324.31+3.32 (+1.03%) ▲|BA172.38-1.02 (-0.59%) ▼|BAC50.55+1.13 (+2.29%) ▲|BKNG163.49+2.83 (+1.76%) ▲|BLK1,214.71+35.84 (+3.04%) ▲|BMY62.14+0.00 (+0.00%) ▲|BNY151.23+3.51 (+2.38%) ▲|BRK-B575.25+4.36 (+0.76%) ▲|C121.97+2.92 (+2.45%) ▲|CAT598.88+40.25 (+7.21%) ▲|CL97.94+1.38 (+1.43%) ▲|CMCSA24.51+0.12 (+0.49%) ▲|COF198.58-3.29 (-1.63%) ▼|COP134.47-1.80 (-1.32%) ▼|COST1,066.18+12.62 (+1.20%) ▲|CRM214.94+1.29 (+0.60%) ▲|CSCO98.65+4.80 (+5.11%) ▲|CVS85.25+1.40 (+1.67%) ▲|CVX210.78-1.83 (-0.86%) ▼|DE691.28+19.63 (+2.92%) ▲|DHR235.12+4.87 (+2.12%) ▲|DIS119.12+2.37 (+2.03%) ▲|DUK128.10+0.32 (+0.25%) ▲|EMR169.52+7.17 (+4.42%) ▲|FDX318.84+10.70 (+3.47%) ▲|GD362.07+8.01 (+2.26%) ▲|GE335.54+12.30 (+3.81%) ▲|GEV829.34+55.23 (+7.13%) ▲|GILD169.32+2.43 (+1.46%) ▲|GM89.65+3.49 (+4.05%) ▲|GOOG286.01+2.08 (+0.73%) ▲|GOOGL288.15+3.37 (+1.18%) ▲|GS906.22+40.40 (+4.67%) ▲|HD353.42+9.95 (+2.90%) ▲|HON229.00+8.95 (+4.07%) ▲|IBM246.11+1.11 (+0.45%) ▲|INTC59.37+3.09 (+5.49%) ▲|INTU338.23-3.27 (-0.96%) ▼|ISRG460.56+7.76 (+1.71%) ▲|JNJ282.11+5.89 (+2.13%) ▲|JPM342.08+7.59 (+2.27%) ▲|KO96.03+0.36 (+0.38%) ▲|LIN520.33+5.08 (+0.99%) ▲|LLY1,411.95+57.95 (+4.28%) ▲|LMT588.19+21.11 (+3.72%) ▲|LOW232.10+7.55 (+3.36%) ▲|LRCX221.31+20.87 (+10.41%) ▲|MA655.81+3.11 (+0.48%) ▲|MCD281.44+4.92 (+1.78%) ▲|MDLZ66.44+0.42 (+0.64%) ▲|MDT102.79+0.99 (+0.97%) ▲|META641.37+31.22 (+5.12%) ▲|MMM188.63+3.48 (+1.88%) ▲|MO75.81-0.31 (-0.41%) ▼|MRK148.76+2.03 (+1.38%) ▲|MS187.10+5.66 (+3.12%) ▲|MSFT545.18+14.57 (+2.75%) ▲|MU733.15+43.15 (+6.25%) ▲|NEE86.86-0.09 (-0.10%) ▼|NFLX63.95+0.54 (+0.85%) ▲|NKE39.88+1.29 (+3.34%) ▲|NOW102.76+0.79 (+0.77%) ▲|NVDA178.67-7.97 (-4.27%) ▼|ORCL119.79+3.69 (+3.18%) ▲|PEP141.88+0.54 (+0.38%) ▲|PFE29.23-0.16 (-0.54%) ▼|PG168.32+2.92 (+1.77%) ▲|PLTR169.20+8.82 (+5.50%) ▲|PM193.12-4.76 (-2.41%) ▼|QCOM171.47+6.06 (+3.66%) ▲|RTX196.31+6.78 (+3.58%) ▲|SBUX109.44+4.03 (+3.82%) ▲|SCHW92.73+1.24 (+1.36%) ▲|SO93.57+1.23 (+1.33%) ▲|SPG233.01+4.59 (+2.01%) ▲|T21.80+0.17 (+0.79%) ▲|TMO721.63+26.87 (+3.87%) ▲|TMUS168.71+6.70 (+4.14%) ▲|TSLA378.05+19.83 (+5.54%) ▲|TXN295.73+18.37 (+6.62%) ▲|UBER71.17+2.58 (+3.76%) ▲|UNH397.62+3.47 (+0.88%) ▲|UNP297.01+6.85 (+2.36%) ▲|UPS110.96+2.66 (+2.46%) ▲|USB60.95+1.50 (+2.52%) ▲|V422.16-0.49 (-0.12%) ▼|VZ46.06+0.37 (+0.81%) ▲|WFC85.49+1.55 (+1.85%) ▲|WMT125.66+0.14 (+0.11%) ▲|XOM164.73-1.14 (-0.69%) ▼|AAPL350.69+8.32 (+2.43%) ▲|ABBV293.30+1.99 (+0.68%) ▲|ABT110.51+0.58 (+0.53%) ▲|ACN254.37-6.13 (-2.35%) ▼|ADBE237.32-1.98 (-0.83%) ▼|AMAT370.55+37.84 (+11.37%) ▲|AMD508.58+59.54 (+13.26%) ▲|AMGN465.23+4.81 (+1.04%) ▲|AMT189.00+0.21 (+0.11%) ▲|AMZN266.93+7.63 (+2.94%) ▲|AVGO319.48+25.79 (+8.78%) ▲|AXP324.31+3.32 (+1.03%) ▲|BA172.38-1.02 (-0.59%) ▼|BAC50.55+1.13 (+2.29%) ▲|BKNG163.49+2.83 (+1.76%) ▲|BLK1,214.71+35.84 (+3.04%) ▲|BMY62.14+0.00 (+0.00%) ▲|BNY151.23+3.51 (+2.38%) ▲|BRK-B575.25+4.36 (+0.76%) ▲|C121.97+2.92 (+2.45%) ▲|CAT598.88+40.25 (+7.21%) ▲|CL97.94+1.38 (+1.43%) ▲|CMCSA24.51+0.12 (+0.49%) ▲|COF198.58-3.29 (-1.63%) ▼|COP134.47-1.80 (-1.32%) ▼|COST1,066.18+12.62 (+1.20%) ▲|CRM214.94+1.29 (+0.60%) ▲|CSCO98.65+4.80 (+5.11%) ▲|CVS85.25+1.40 (+1.67%) ▲|CVX210.78-1.83 (-0.86%) ▼|DE691.28+19.63 (+2.92%) ▲|DHR235.12+4.87 (+2.12%) ▲|DIS119.12+2.37 (+2.03%) ▲|DUK128.10+0.32 (+0.25%) ▲|EMR169.52+7.17 (+4.42%) ▲|FDX318.84+10.70 (+3.47%) ▲|GD362.07+8.01 (+2.26%) ▲|GE335.54+12.30 (+3.81%) ▲|GEV829.34+55.23 (+7.13%) ▲|GILD169.32+2.43 (+1.46%) ▲|GM89.65+3.49 (+4.05%) ▲|GOOG286.01+2.08 (+0.73%) ▲|GOOGL288.15+3.37 (+1.18%) ▲|GS906.22+40.40 (+4.67%) ▲|HD353.42+9.95 (+2.90%) ▲|HON229.00+8.95 (+4.07%) ▲|IBM246.11+1.11 (+0.45%) ▲|INTC59.37+3.09 (+5.49%) ▲|INTU338.23-3.27 (-0.96%) ▼|ISRG460.56+7.76 (+1.71%) ▲|JNJ282.11+5.89 (+2.13%) ▲|JPM342.08+7.59 (+2.27%) ▲|KO96.03+0.36 (+0.38%) ▲|LIN520.33+5.08 (+0.99%) ▲|LLY1,411.95+57.95 (+4.28%) ▲|LMT588.19+21.11 (+3.72%) ▲|LOW232.10+7.55 (+3.36%) ▲|LRCX221.31+20.87 (+10.41%) ▲|MA655.81+3.11 (+0.48%) ▲|MCD281.44+4.92 (+1.78%) ▲|MDLZ66.44+0.42 (+0.64%) ▲|MDT102.79+0.99 (+0.97%) ▲|META641.37+31.22 (+5.12%) ▲|MMM188.63+3.48 (+1.88%) ▲|MO75.81-0.31 (-0.41%) ▼|MRK148.76+2.03 (+1.38%) ▲|MS187.10+5.66 (+3.12%) ▲|MSFT545.18+14.57 (+2.75%) ▲|MU733.15+43.15 (+6.25%) ▲|NEE86.86-0.09 (-0.10%) ▼|NFLX63.95+0.54 (+0.85%) ▲|NKE39.88+1.29 (+3.34%) ▲|NOW102.76+0.79 (+0.77%) ▲|NVDA178.67-7.97 (-4.27%) ▼|ORCL119.79+3.69 (+3.18%) ▲|PEP141.88+0.54 (+0.38%) ▲|PFE29.23-0.16 (-0.54%) ▼|PG168.32+2.92 (+1.77%) ▲|PLTR169.20+8.82 (+5.50%) ▲|PM193.12-4.76 (-2.41%) ▼|QCOM171.47+6.06 (+3.66%) ▲|RTX196.31+6.78 (+3.58%) ▲|SBUX109.44+4.03 (+3.82%) ▲|SCHW92.73+1.24 (+1.36%) ▲|SO93.57+1.23 (+1.33%) ▲|SPG233.01+4.59 (+2.01%) ▲|T21.80+0.17 (+0.79%) ▲|TMO721.63+26.87 (+3.87%) ▲|TMUS168.71+6.70 (+4.14%) ▲|TSLA378.05+19.83 (+5.54%) ▲|TXN295.73+18.37 (+6.62%) ▲|UBER71.17+2.58 (+3.76%) ▲|UNH397.62+3.47 (+0.88%) ▲|UNP297.01+6.85 (+2.36%) ▲|UPS110.96+2.66 (+2.46%) ▲|USB60.95+1.50 (+2.52%) ▲|V422.16-0.49 (-0.12%) ▼|VZ46.06+0.37 (+0.81%) ▲|WFC85.49+1.55 (+1.85%) ▲|WMT125.66+0.14 (+0.11%) ▲|XOM164.73-1.14 (-0.69%) ▼|
9.6 C
New York
Tuesday, November 10, 2026

Tag: results

newsFORsourcecompanycontentinformationreleases1IT

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – 
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

Andrew Peller Ltd. Announces Timing of Q1 2026 Results & Conference Call

GRIMSBY, Ontario, July 18, 2025 (GLOBE NEWSWIRE) -- Andrew Peller Limited (ADW.A / ADW.B) will issue its financial results for the three months ended June 30, 2025, after close of market on Wednesday, August 6, 2025. Management will host a conference call to discuss the financial results on Thursday, August 7, 2025, at 10:00 a.m. (ET), followed by a question-and-answer period.

Hapbee Reports First-Ever Quarterly Profit in Q2 2025 and Achieves Third Consecutive Quarter of Growth

Strong top-line gains, reduced expenditures, and improved gross margins result in milestone quarter 
Strong top-line gains, reduced expenditures, and improved gross margins result in milestone quarter

Timbercreek Financial Announces Conference Call to Discuss Second Quarter Financial Results

TORONTO, July 18, 2025 (GLOBE NEWSWIRE) -- Timbercreek Financial (TSX: TF) will hold a conference call and live audio webcast at 1:00 p.m. (ET) on Thursday, July 31, 2025, to discuss financial results for the quarter ended June 30, 2025. The financial results will be released on Wednesday, July 30, 2025, after the markets close. Interested parties are invited to participate in the call with management which will be followed by a question and answer period with analysts.

Capella Provides Update on Agreement with Tümad Madencilik

www.capellaminerals.com VANCOUVER, BC, July 18, 2025 /CNW/ - Capella Minerals Ltd (TSXV: CMIL) (OTC Pink: CMILF) (FRA: N7D2) ("Capella" or the "Company") is pleased to...

LOVESAC AND VAN LEEUWEN UNVEIL LIMITED-EDITION COLLABORATION AHEAD OF NATIONAL ICE CREAM DAY

The brands are teaming up to celebrate 10 years of Van Leeuwen's fan-favorite Honeycomb flavor with custom CitySac Covers, $3 scoops, giveaways and a celebration in...

Muscle Gain & Strength Supplements: How CrazyBulk Muscle Building Supplements Boost Strength and Maximize Muscle Performance Fast

Explore how CrazyBulk legal muscle building supplements power muscle gain, improve muscle strength, and unlock next-level muscle performance in 2025. 
Explore how CrazyBulk legal muscle building supplements power muscle gain, improve muscle strength, and unlock next-level muscle performance in 2025.

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions

Roundhouse Provisions Basecamp Complete Wins “Meal Replacement Product of the Year” at 2025 Mindful Awards

Plant-Based, Chuck Norris-Approved Nutrition Shake Recognized for Exceptional Convenience, Taste, and Nutritional Balance HOUSTON, July 18, 2025 /PRNewswire/ -- Roundhouse Provisions®, the trusted wellness brand...

Why a 72-year-old American CEO wants to move his factory to China – What makes China’s supply chain so attractive?

BEIJING, July 18, 2025 /PRNewswire/ -- A news report from China.org.cn on China's supply chain:   Jeff Bowman, a 72-year-old American CEO, is considering moving his factory...

Unisys Takes Meaningful Steps to Remove U.S. Pension Volatility and Accelerate Path to Full Removal

Management invites investors to webcast to discuss benefits of recent capitalstructure transformation BLUE BELL, Pa., July 18, 2025 /PRNewswire/ -- Unisys (NYSE: UIS) today announced...

MLB Is Back. The Best MLB Baseball Handicapper, BASports.com, Roared Last Year

In the month after the last All-Star-Break, BASports.com had 5 times more profit than anyone else WAUCHULA, Fla., July 18, 2025 /PRNewswire/ -- MLB Baseball...

Calumet, Inc. to Release Second Quarter 2025 Earnings on August 8, 2025

INDIANAPOLIS, July 18, 2025 /PRNewswire/ -- Calumet, Inc. (NASDAQ: CLMT) (the "Company," "Calumet," "we," "our" or "us"), announced today that it plans to report...

Results of the Stellantis 2025 Extraordinary General Meeting of Shareholders

Results of the Stellantis 2025 Extraordinary General Meeting of Shareholders

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResults

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers